Home › Research › Laboratory science
Lymphoid gene expression supports neuroprotective microglia function
Ayata P, Crowley JM, Challman MF, Sahasrabuddhe V, Gratuze M, Werneburg S, et al. (Schaefer A senior author). Nature, 2025-11-05
Topic: Brain proteins, microglia and lab models
This is primarily a mouse-model study (in amyloid-plaque mouse models such as 5xFAD, with some human tissue validation) identifying a newly recognized, protective state of brain immune cells (microglia) that expresses genes normally associated with the immune system's lymphocytes. The protective state is controlled by a protein called PU.1, and artificially lowering PU.1 reduced amyloid-related brain damage in mice. Because the core experiments are in mice, this is early-stage mechanistic evidence about a potential future drug target, not a human treatment finding.
Key findings
- Identified a microglial subpopulation enriched for lymphoid-associated genes that is neuroprotective against amyloid pathology
- This protective state is controlled by the transcription factor PU.1, which normally decreases when microglia contact amyloid plaques
- Experimentally lowering PU.1 in microglia reduced severity of amyloid pathology in mouse models
- The lymphoid receptor gene CD28 was identified as important for microglia-mediated synaptic protection
Why it matters
In mouse models, researchers identified a protective state of brain immune cells controlled by the protein PU.1, and lowering PU.1 reduced amyloid-related brain damage. Because the core experiments were in mice, this is early-stage evidence about a possible future drug target, not a human treatment finding.
Study details
- Effect sizeLowering PU.1 reduced amyloid-related brain damage in mouse models (no single numeric effect size reported)
- Evidence strengthEarly
Limitations
Core experiments were conducted in mice; this is preclinical work not yet demonstrated in humans, and no specific human sample size is given.
How this study scored 45/100
Published in a top-tier journal. Scored zero for study design, sample size, studied in people, randomised / blinded and indexed in PubMed because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 28 of the 62 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Nature) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 2 / 5 | Rated “early” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 0 / 2 | No PubMed ID and no DOI — scores zero (not stated in the record — scored 0) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 28 / 62 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 28 of the 62 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Ayata, P., Crowley, J. M., Challman, M. F., Sahasrabuddhe, V., Gratuze, M., Werneburg, S., et al. (2025). Lymphoid gene expression supports neuroprotective microglia function. Nature.
Vancouver
Ayata P, Crowley JM, Challman MF, Sahasrabuddhe V, Gratuze M, Werneburg S, et al. Lymphoid gene expression supports neuroprotective microglia function. Nature. 2025.
BibTeX
@article{ayata2025-1378ad15,
author = {Ayata, P. and Crowley, J. M. and Challman, M. F. and Sahasrabuddhe, V. and Gratuze, M. and Werneburg, S. and others},
title = {{Lymphoid gene expression supports neuroprotective microglia function}},
journal = {Nature},
year = {2025}
}